The Effct of Chitooligosaccharide on Immune Function in Healthy Adults
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Functional properties of chitooligosaccharides have been studied for antitumor activity, immunostimulating effects, antimicrobial activity, free radical scavening activity, adn angiotensin I converting enzyme inhibitory activity. Recent in vitro, and in vivo toxicity and absorbability studies have demonstrated that chitooligosaccharides have high absorbability and are essentially non-toxic. In the present study, we prepared a chitooligosaccharide with high absorbability and evaluated its effects on activation of immune function and cardiovascular funciton(lipid, atrial stiffness, etc) in healthy adults.
This study was a 8-week, randomized, double-blind clinical trial. The 30 volunteers were divided into a control group(n=10), half dose chitooligosaccaride(FACOSTM) intake group(n=10), and full dose FACOS intake group(n=10). Peripheral blood mononuclear cells(PBMCs) were isolated and cultured in 12 well plate for 48 hours. Cytokine production by PBMCs pre- and postintervention were measured simultaneously after stimulation with lipopolysaccaride.
| Condition | Intervention | Phase |
|---|---|---|
|
Immunity |
Drug: FACOS (functional food) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind |
Eligibility| Ages Eligible for Study: | 20 Years to 50 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
- healthy adults(the ages between 20~50 year)
Exclusion Criteria:
- food allergy and allergy skin disease
- severe liver and kidney disease
- pregnant, lactating women
- cancer, stroke, etc.
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00468962 History of Changes |
| Other Study ID Numbers: | 07-05 |
| Study First Received: | May 2, 2007 |
| Last Updated: | May 2, 2007 |
| Health Authority: | Korea: Food and Drug Administration |
ClinicalTrials.gov processed this record on May 21, 2013